HIGHLIGHTS OF A SYMPOSIUM: Risk Reduction and the GI Tract: From Theory to Reality
A supplement to Family Practice News supported by TAP Pharmaceuticals Inc. This supplement is jointly sponsored by Medical Education Collaborative (MEC), a not-for-profit company, and International Medical News Group. MEC is accredited by the ACCME to provide continuing medical education for physicians.
Clinical Highlights of articles are based on presentations given at a continuing medical education symposium held on May 18, 2003.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 5.
Contents
Introduction
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Center
Hamilton, Ontario, Canada Consultant/Speaker: TAP, AstraZeneca, Merck, Axcan Pharma, Inc.
The Measurement and Expression of Risk: An Overview
Robert S. Sandler, MD, MPH
Professor of Medicine and Epidemiology
Chief, Division of Digestive Diseases and Nutrition
University of North Carolina at Chapel Hill
Chapel Hill, NC Nothing to disclose.
Prevention of Dyspepsia, Ulcers, and Complications: Appropriate Use of PPIs to Minimize GI Mucosal Injury
David J. Bjorkman, MD, MSPH, SM (Epid.)
Professor of Medicine
Senior Associate Dean
University of Utah School of Medicine
Salt Lake City, UT Nothing to disclose.
Gastroesophageal Reflux Disease: Could Early Intervention Reduce the Risk of Progression to Cancer?
Brian J. Reid, MD, PhD
Member, Divisions of Human Biology and Public Health Sciences
Fred Hutchinson Cancer Research
Seattle, WA Grants: U.S. National Institutes of Health; Consultant: Strategic Consultants International; Financial Interest in Epigenomics.
The Natural History of Reflux Esophagitis: Does the Problem Start in Childhood?
Benjamin D. Gold, MD
Associate Professor of Pediatrics and Microbiology
Director, Division of Pediatric Gastroenterology and Nutrition
Emory University
Atlanta, GA Consultant: TAP Pharmaceuticals. He discusses the unlabeled use of proton pump inhibitors in infancy and supraesophageal GERD.
Target Audience
This activity has been developed for physicians involved in the treatment of gastrointestinal disorders.
Needs Assessment
The spectrum of gastrointestinal risk encompasses a wide range of diseases and disorders. The conditions include mucosal injury induced by chronic treatment with nonsteroidal antiinflammatory drugs, gastroesophageal reflux disease, reflux esophagitis, Barrett's esophagus, esophageal cancer, and gastric cancer. Each of the conditions affords potential opportunities for risk reduction. By recognizing the opportunities and intervening appropriately, clinicians can reduce the morbidity and mortality associated with gastrointestinal diseases and perhaps prevent many of their serious clinical consequences.
Learning Objectives
Upon completion of this continuing medical education activity, readers should be able to
• Discuss different approaches to assessment and expression of gastrointestinal risk and to recognize the advantages and disadvantages of each approach.
• Understand the gastrointestinal risks associated with chronic antiinflammatory therapy and options for reducing the risks.
• Appreciate the factors associated with the increased prevalence of adenocarcinoma of the esophagus and recognize potentially beneficial strategies to reduce the cancer risk.
• Evaluate the evidence from studies of dietary interventions to reduce the risk of gastrointestinal cancer.
• Understand current evidence regarding the role of Helicobacter pylori eradication in the prevention of gastric cancer.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Collaborative (MEC), a not-for-profit company, and International Medical News Group. MEC is accredited by the ACCME to provide continuing medical education for physicians.
MEC designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.
